open access

Vol 65, No 8 (2007)
Other
Published online: 2007-08-29
Submitted: 2012-12-28
Get Citation

Original article
Analysis of apoptotic markers Fas/FasL (CD95/CD95L) expression on the lymphocytes in patients with acute coronary syndrome

Anna Bossowska, Artur Bossowski, Bogdan Galar
Kardiol Pol 2007;65(8):883-889.

open access

Vol 65, No 8 (2007)
Other
Published online: 2007-08-29
Submitted: 2012-12-28

Abstract

Background: Acute coronary syndromes are caused by the rupture or erosion of an atherosclerotic plaque which by secreting a variety of proteases is capable of degrading pericellular matrix components induces death of endothelial cells. This mechanism plays the main role in apoptosis.
Aim:
To estimate expression of apoptotic Fas/FasL (CD95/CD95L) on lymphocytes in the peripheral blood.
Methods:
We examined patients with acute myocardial infarction (n=18, mean age 62±8 years), in unstable angina pectoris (n=31, mean age 62±10 years) and in a control group (n=20, mean age 62±9 years) without coronary risk factors and inflammatory condition. All investigations of Fas/FasL were performed by flow cytometry. Inflammatory parameters and standard risk factors were investigated by standard methods (ELISA).
Results:
The analysis revealed a higher expression of Fas and FasL molecules on the lymphocytes from patients with acute myocardial infarction (p <0.001, p <0.002) and unstable angina (p <0.01, p <0.02) compared to the control group. Moreover we found a statistically significant positive correlation between the level of LDL cholesterol and hypertension and prevalance of CD95 (p <0.001, p <0.01) and CD95L (p <0.02, p <0.03) in patients with acute myocardial infarction.
Conclusions:
A higher expression of apoptotic molecules (Fas and FasL) on lymphocytes occurs before the onset of acute ischaemia and contributes to the plaque rupture and acute coronary syndrome. Furthermore, antiapoptotic therapy leads to plaque stabilisation.

Abstract

Background: Acute coronary syndromes are caused by the rupture or erosion of an atherosclerotic plaque which by secreting a variety of proteases is capable of degrading pericellular matrix components induces death of endothelial cells. This mechanism plays the main role in apoptosis.
Aim:
To estimate expression of apoptotic Fas/FasL (CD95/CD95L) on lymphocytes in the peripheral blood.
Methods:
We examined patients with acute myocardial infarction (n=18, mean age 62&#177;8 years), in unstable angina pectoris (n=31, mean age 62&#177;10 years) and in a control group (n=20, mean age 62&#177;9 years) without coronary risk factors and inflammatory condition. All investigations of Fas/FasL were performed by flow cytometry. Inflammatory parameters and standard risk factors were investigated by standard methods (ELISA).
Results:
The analysis revealed a higher expression of Fas and FasL molecules on the lymphocytes from patients with acute myocardial infarction (p <0.001, p <0.002) and unstable angina (p <0.01, p <0.02) compared to the control group. Moreover we found a statistically significant positive correlation between the level of LDL cholesterol and hypertension and prevalance of CD95 (p <0.001, p <0.01) and CD95L (p <0.02, p <0.03) in patients with acute myocardial infarction.
Conclusions:
A higher expression of apoptotic molecules (Fas and FasL) on lymphocytes occurs before the onset of acute ischaemia and contributes to the plaque rupture and acute coronary syndrome. Furthermore, antiapoptotic therapy leads to plaque stabilisation.
Get Citation

Keywords

myocardial infarction; unstable angina; apoptosis

About this article
Title

Original article
Analysis of apoptotic markers Fas/FasL (CD95/CD95L) expression on the lymphocytes in patients with acute coronary syndrome

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 65, No 8 (2007)

Pages

883-889

Published online

2007-08-29

Bibliographic record

Kardiol Pol 2007;65(8):883-889.

Keywords

myocardial infarction
unstable angina
apoptosis

Authors

Anna Bossowska
Artur Bossowski
Bogdan Galar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl